Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Tecartus (Great Britain) {equilateral_black_triangle}

Active Ingredient:
brexucabtagene autoleucel
Company:  
Gilead Sciences Ltd See contact details
ATC code: 
L01XL06
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

TECARTUS_Handling Guide

{healthcare_pro_orange} For Healthcare Professionals
Guide to handling and method of administration, and sampling recommendation for secondary malignancy: To minimize the potential risk of decrease in viability of the product loss of efficacy due to inappropriate preparation of the Tecartus infusion.
{pdf_link}

TECARTUS_HCP Educational Guide

{healthcare_pro_orange} For Healthcare Professionals
Healthcare provider (HCP) educational material - To inform HCPs on how to monitor and manage symptoms associated with CRS and serious neurologic adverse reactions, and provide guidance on reporting these serious adverse reactions associated with Tecartus.
{pdf_link}

TECARTUS_Patient Alert Card

Patient Alert Card - To inform patients of the risks of CRS and serious neurologic adverse reactions, associated with Tecartus.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Gilead Sciences Ltd
Company image
Address
280 High Holborn, London, WC1V 7EE, UK
Telephone
+44 (0)203 681 4500
E-mail
[email protected]
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)203 681 4681
Customer Care direct line
+353 1 291 3580 (Ireland)
Medical Information Direct Line
08000 113 700 (UK)
Medical Information Direct Line
+353 214 825 999 (Ireland)